Inhibition of BAP1 Sensitizes Gastric Cancer Cells to 5-Fluorouracil by Promoting BIRC5 Degradation.
- 1Department of Biochemistry and Molecular Biology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
- 2Department of General Surgery, Hallym University College of Medicine, Hallym Medical Center, Anyang 14068, Republic of Korea.
Abstract
Background/Objectives: Gastric cancer is an aggressive malignancy with poor prognosis, and acquired resistance to 5-fluorouracil (5-FU) remains a major therapeutic challenge. BRCA1-associated protein-1 (BAP1), a deubiquitinating enzyme, has been implicated in tumorigenesis; however, its role in gastric cancer and 5-FU resistance remains unclear. This study investigated the functional and molecular roles of BAP1 in gastric cancer progression and chemoresistance. Methods: BAP1 expression and its association with patient prognosis were evaluated in gastric cancer tissues. The effects of BAP1 depletion on cancer cell proliferation, migration, invasion, and apoptosis were examined. The interaction between BAP1 and BIRC5 (Survivin) and the effects of BAP1-mediated deubiquitination on BIRC5 stability were investigated. The therapeutic effect of the BAP1 inhibitor iBAP-II was further assessed in 5-FU resistant gastric cancer cells. Results: BAP1 was significantly upregulated in gastric cancer tissues and associated with poor prognosis. BAP1 knockdown suppressed proliferation, migration, and invasion. Further analysis revealed that BAP1 interacted with and stabilized BIRC5 through deubiquitination, thereby suppressing apoptosis. BAP1 and BIRC5 were markedly upregulated in 5-FU resistant cells, whereas iBAP-II treatment enhanced 5-FU sensitivity and increased caspase-3 and PARP cleavage. Conclusions: BAP1 promotes gastric cancer progression and 5-FU resistance by stabilizing BIRC5. Targeting the BAP1-BIRC5 axis may represent a promising strategy for overcoming 5-FU resistance and improving therapeutic efficacy in gastric cancer.
Related
- HDAC inhibition drives NOX5-dependent oxidative stress and sensitizes uveal melanoma cells to SOD1 inhibition
- Inhibition of WNT signaling sensitizes CRC cells to anti-tumor effects of retinoids: basis for new drug combinations in oncology.
- Identification of YL064 as a novel inhibitor of ATXN3 to suppress tumor growth and metastasis by promoting degradation of oncogenic substrates.
- TRIM26-Mediated Ubiquitination and Degradation of DDRGK1 Suppress NSCLC Progression by Inhibiting DNA Repair and Promoting Apoptosis
- From Inhibition to Degradation: Can Galectin-3 Be Drugged by Heterobifunctional Degraders?
BibTeX
@article{jeong2026inhibition,
title = {{Inhibition of BAP1 Sensitizes Gastric Cancer Cells to 5-Fluorouracil by Promoting BIRC5 Degradation.}},
author = {In-Ho Jeong and Yu-Jin Park and Min-Jee Kim and Eun Ju Lee and Byung Sik Kim and Hee-Sung Kim and Peter Chang-Whan Lee},
journal = {Pharmaceuticals (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/ph19101593},
url = {https://europepmc.org/article/MED/42943290},
note = {CC BY},
}
RIS
TY - JOUR
TI - Inhibition of BAP1 Sensitizes Gastric Cancer Cells to 5-Fluorouracil by Promoting BIRC5 Degradation.
AU - In-Ho Jeong
AU - Yu-Jin Park
AU - Min-Jee Kim
AU - Eun Ju Lee
AU - Byung Sik Kim
AU - Hee-Sung Kim
AU - Peter Chang-Whan Lee
PY - 2026
DA - 2026/10/08
JO - Pharmaceuticals (Basel, Switzerland)
DO - 10.3390/ph19101593
UR - https://europepmc.org/article/MED/42943290
AB - Background/Objectives: Gastric cancer is an aggressive malignancy with poor prognosis, and acquired resistance to 5-fluorouracil (5-FU) remains a major therapeutic challenge. BRCA1-associated protein-1 (BAP1), a deubiquitinating enzyme, has been implicated in tumorigenesis; however, its role in gastric cancer and 5-FU resistance remains unclear. This study investigated the functional and molecular roles of BAP1 in gastric cancer progression and chemoresistance. Methods: BAP1 expression and its association with patient prognosis were evaluated in gastric cancer tissues. The effects of BAP1 depletion on cancer cell proliferation, migration, invasion, and apoptosis were examined. The interaction between BAP1 and BIRC5 (Survivin) and the effects of BAP1-mediated deubiquitination on BIRC5 stability were investigated. The therapeutic effect of the BAP1 inhibitor iBAP-II was further assessed in 5-FU resistant gastric cancer cells. Results: BAP1 was significantly upregulated in gastric cancer tissues and associated with poor prognosis. BAP1 knockdown suppressed proliferation, migration, and invasion. Further analysis revealed that BAP1 interacted with and stabilized BIRC5 through deubiquitination, thereby suppressing apoptosis. BAP1 and BIRC5 were markedly upregulated in 5-FU resistant cells, whereas iBAP-II treatment enhanced 5-FU sensitivity and increased caspase-3 and PARP cleavage. Conclusions: BAP1 promotes gastric cancer progression and 5-FU resistance by stabilizing BIRC5. Targeting the BAP1-BIRC5 axis may represent a promising strategy for overcoming 5-FU resistance and improving therapeutic efficacy in gastric cancer.
SN - 1424-8247
ER -